Design, Synthesis and Evaluation of New Indolylpyrimidylpiperazines for Gastrointestinal Cancer Therapy
Please always quote using this URN: urn:nbn:de:bvb:20-opus-193271
- Human A3 adenosine receptor hA3AR has been implicated in gastrointestinal cancer, where its cellular expression has been found increased, thus suggesting its potential as a molecular target for novel anticancer compounds. Observation made in our previous work indicated the importance of the carbonyl group of amide in the indolylpyrimidylpiperazine (IPP) for its human A2A adenosine receptor (hA2AAR) subtype binding selectivity over the other AR subtypes. Taking this observation into account, we structurally modified an indolylpyrimidylpiperazineHuman A3 adenosine receptor hA3AR has been implicated in gastrointestinal cancer, where its cellular expression has been found increased, thus suggesting its potential as a molecular target for novel anticancer compounds. Observation made in our previous work indicated the importance of the carbonyl group of amide in the indolylpyrimidylpiperazine (IPP) for its human A2A adenosine receptor (hA2AAR) subtype binding selectivity over the other AR subtypes. Taking this observation into account, we structurally modified an indolylpyrimidylpiperazine (IPP) scaffold, 1 (a non-selective adenosine receptors’ ligand) into a modified IPP (mIPP) scaffold by switching the position of the carbonyl group, resulting in the formation of both ketone and tertiary amine groups in the new scaffold. Results showed that such modification diminished the A2A activity and instead conferred hA3AR agonistic activity. Among the new mIPP derivatives (3–6), compound 4 showed potential as a hA3AR partial agonist, with an Emax of 30% and EC50 of 2.89 ± 0.55 μM. In the cytotoxicity assays, compound 4 also exhibited higher cytotoxicity against both colorectal and liver cancer cells as compared to normal cells. Overall, this new series of compounds provide a promising starting point for further development of potent and selective hA3AR partial agonists for the treatment of gastrointestinal cancers.…
Author: | Aaron Tan, Maria V. Babak, Gopalakrishnan Venkatesan, Clarissa Lim, Karl-Norbert Klotz, Deron Raymond Herr, Siew Lee Cheong, Stephanie Federico, Giampiero Spalluto, Wei-Yi Ong, Yu Zong Chen, Jason Siau Ee Loo, Giorgia Pastorin |
---|---|
URN: | urn:nbn:de:bvb:20-opus-193271 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Institut für Pharmakologie und Toxikologie |
Language: | English |
Parent Title (English): | Molecules |
ISSN: | 1420-3049 |
Year of Completion: | 2019 |
Volume: | 24 |
Issue: | 20 |
Pagenumber: | 3661 |
Source: | Molecules 2019, 24(20), 3661; https://doi.org/10.3390/molecules24203661 |
DOI: | https://doi.org/10.3390/molecules24203661 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Tag: | gastrointestinal cancer; hA<sub>3</sub>AR; indolylpyrimidylpiperazines; partial agonists |
Release Date: | 2020/10/20 |
Date of first Publication: | 2019/10/11 |
Licence (German): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |